- Home
- MPB vs TYRA Comparison
MPB vs TYRA Comparison
Compare MPB & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- TYRA
- Stock Information
- Founded
- MPB 1868
- TYRA 2018
- Country
- MPB United States
- TYRA United States
- Employees
- MPB N/A
- TYRA 60
- Industry
- MPB Major Banks
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- TYRA Health Care
- Exchange
- MPB Nasdaq
- TYRA Nasdaq
- Market Cap
- MPB 628.8M
- TYRA 571.9M
- IPO Year
- MPB N/A
- TYRA 2021
- Fundamental
- Price
- MPB $28.13
- TYRA $10.73
- Analyst Decision
- MPB Buy
- TYRA Strong Buy
- Analyst Count
- MPB 2
- TYRA 7
- Target Price
- MPB $34.50
- TYRA $30.86
- AVG Volume (30 Days)
- MPB 122.8K
- TYRA 193.5K
- Earning Date
- MPB 07-23-2025
- TYRA 08-14-2025
- Dividend Yield
- MPB 2.84%
- TYRA N/A
- EPS Growth
- MPB N/A
- TYRA N/A
- EPS
- MPB 2.30
- TYRA N/A
- Revenue
- MPB $191,454,000.00
- TYRA N/A
- Revenue This Year
- MPB $24.31
- TYRA N/A
- Revenue Next Year
- MPB $13.74
- TYRA N/A
- P/E Ratio
- MPB $12.22
- TYRA N/A
- Revenue Growth
- MPB 13.34
- TYRA N/A
- 52 Week Low
- MPB $22.50
- TYRA $6.42
- 52 Week High
- MPB $33.87
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- MPB 52.30
- TYRA 51.71
- Support Level
- MPB $27.10
- TYRA $10.32
- Resistance Level
- MPB $28.85
- TYRA $11.08
- Average True Range (ATR)
- MPB 0.54
- TYRA 0.64
- MACD
- MPB 0.14
- TYRA -0.05
- Stochastic Oscillator
- MPB 67.86
- TYRA 42.44
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.